var data={"title":"Calcitonin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcitonin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5784?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcitonin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcitonin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=calcitonin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Calcitonin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144121\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fortical [DSC];</li>\n      <li>Miacalcin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144122\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Calcimar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144166\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Hormone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144125\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paget's disease, symptomatic:</b> IM, SubQ: 100 units daily. Lower maintenance dosages (eg, 50 units 3 times/week) may be sufficient (DeRose 1974)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercalcemia:</b> Initial: IM, SubQ: 4 units/kg every 12 hours; may increase up to 8 units/kg every 6 to 12 hours; hypocalcemic effect of calcitonin diminishes after 24 to 48 hours (Bilezikian 1993; Nilsson 1978; Stevenson 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postmenopausal osteoporosis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, SubQ: 100 units daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 200 units (1 spray) in one nostril once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144126\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682377\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682378\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144099\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miacalcin: 200 units/mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortical: 200 units/actuation (3.7 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miacalcin: 200 units/actuation (3.7 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 units/actuation (3.7 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144084\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24825758\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Solution, Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Calcimar: 200 units/mL (2 mL) [contains phenol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144103\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: May be administered IM or SubQ. IM route is preferred if the injection volume is &gt;2 mL (use multiple injection sites if dose volume is &gt;2 mL). SubQ route is preferred for outpatient self-administration unless the injection volume is &gt;2 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasal spray: Before first use, allow bottle to reach room temperature, then prime pump by releasing until a full spray is produced. To administer, place nozzle into nostril with head in upright position. Alternate nostrils daily. Do not prime pump before each daily use. Discard after 30 doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144102\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;\">Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypercalcemia:</b> Adjunctive therapy for hypercalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paget disease:</b> Treatment of symptomatic Paget disease of bone (osteitis deformans) in patients who are nonresponsive or intolerant to alternative therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postmenopausal osteoporosis:</b> Treatment of  osteoporosis in women more than 5 years postmenopause</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postmenopausal osteoporosis:</b> Treatment of postmenopausal osteoporosis in women more than 5 years postmenopause</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144173\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calcitonin may be confused with calcitriol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortical may be confused with Foradil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miacalcin may be confused with Micatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calcitonin nasal spray is administered as a single spray into <b>one</b> nostril daily, using alternate nostrils each day.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144091\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Unless otherwise noted, frequencies reported are with nasal spray.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%: Respiratory: Rhinitis (&lt;12%, including ulcerative)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing (injection: 2% to 5%, hands or face; nasal spray: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Depression (1% to 3%), dizziness (1% to 3%), paresthesia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Erythematous rash (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (injection: 10%; nasal spray: 1% to 3%), abdominal pain (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Malignant neoplasm (5%), lymphadenopathy (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (injection: 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (5%), myalgia (1% to 3%), osteoarthritis (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Abnormal lacrimation (1% to 3%), conjunctivitis (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchospasm (1% to 3%), flu-like symptoms (1% to 3%), sinusitis (1% to 3%), upper respiratory tract infection (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (all routes): Alopecia, altered sense of smell, anaphylactic shock, anaphylactoid reaction, anaphylaxis, anorexia, antibody development (drug efficacy can be affected), arthralgia, casts in urine, cough, decreased appetite (injection), diaphoresis, diarrhea, dysgeusia, dyspnea, earlobe pruritus (injection), edema, excoriation (nasal mucosa), eye pain, facial edema, fever, headache, hearing loss, hypersensitivity reaction, hypertension, hypocalcemia, musculoskeletal pain, nasal mucosa ulcer, nocturia, pedal edema, peripheral edema, polyuria, pruritus, salty taste (injection), skin rash, sneezing, tachycardia, tinnitus, tremor, urine abnormality, urticaria (injection), visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144106\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to calcitonin salmon or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144088\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Salmon-derived products: Anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat have been reported; have epinephrine immediately available for a possible hypersensitivity reaction. A skin test should be performed prior to initiating therapy of calcitonin salmon in patients with suspected sensitivity; a detailed skin testing protocol is available from the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Hypocalcemia with tetany and seizure activity has been reported. Hypocalcemia and other disorders affecting mineral metabolism (eg, vitamin D deficiency) should be corrected before initiating therapy; monitor serum calcium and symptoms of hypocalcemia during therapy. Administer in conjunction with calcium and vitamin D.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Analyses of randomized controlled trials (in osteoporosis and osteoarthritis) using the nasal spray and oral formulations have demonstrated a statistically significant increase in the risk of the development of cancer in calcitonin-treated patients (compared to placebo). The risk for malignancies is associated with long-term use of calcitonin (trials ranged from 6 months to 5 years in duration). Periodically reassess continued use of calcitonin therapy, carefully considering the risks versus benefits. Similar risk for other routes (subcutaneous, IM, IV) cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary sediment abnormalities: Coarse granular casts and casts containing renal tubular epithelial cells were observed following use in young adults on bed rest during a study to examine the effect of immobilization on osteoporosis; no other renal abnormalities were reported and sediment normalized after discontinuation; consider monitoring urine sediment periodically; however, the clinical significance of this finding is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Risk vs benefit: Definitive efficacy of calcitonin-salmon in decreasing fractures is lacking compared to other agents approved for osteoporosis treatment. Consider potential benefits of therapy against risks, including the potential risk for malignancy with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nasal spray: Rhinitis and epistaxis have been reported; mucosal alterations may occur. Perform nasal examinations with visualization of the nasal mucosa, turbinates, septum and mucosal blood vessels prior to initiation of therapy, periodically during therapy, and at any time nasal symptoms occur. Temporarily withdraw use if ulceration of nasal mucosa occurs. Discontinue for severe ulcerations &gt;1.5 mm, those that penetrate below the mucosa, or those associated with heavy bleeding. Patients &gt;65 years of age may experience a higher incidence of nasal adverse events with calcitonin nasal spray.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Fracture reduction efficacy has not been demonstrated; use has not been shown to increase spinal bone mineral density in early postmenopausal women. Use should be reserved for patients for whom alternative treatments are not suitable (eg, patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298928\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218757\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9182&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Calcitonin may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoledronic Acid: Calcitonin may enhance the hypocalcemic effect of Zoledronic Acid. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144095\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1861980\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Miacalcin is not indicated for use in women of reproductive potential. Adverse events have been observed in animal reproduction studies. Calcitonin does not cross the placenta.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144109\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Miacalcin is not indicated for use in women of reproductive potential. It is not known if calcitonin is excreted in human breast milk. The manufacturer recommends that caution be exercised when administering calcitonin to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144110\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Patients with Paget's disease and hypercalcemia should follow a low calcium diet as prescribed. Recommended amounts of vitamin D and calcium intake is essential for preventing/treating osteoporosis. If dietary intake is inadequate, dietary supplementation is recommended. Women and men should consume:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Calcium: 1,000 mg/day (men: 50  to 70 years) <b>or</b> 1,200 mg/day (women &ge;51 years and men &ge;71 years) (IOM, 2011; NOF [Cosman 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vitamin D: 800  to 1,000 units/day (men and women &ge;50 years) (NOF [Cosman, 2014]). Recommended Dietary Allowance (RDA): 600 units/day (men and women &le;70 years) <b>or</b> 800 units/day (men and women &ge;71 years) (IOM, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144097\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteoporosis: Bone mineral density (BMD) should be evaluated 1 to 2 years after initiating therapy and every 2 years thereafter (NOF [Cosman, 2014]); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; consider measuring biochemical markers of bone turnover</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paget disease: Alkaline phosphatase; pain; serum calcium and 25(OH)D</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasal formulation: Visualization of nasal mucosa, turbinate, septum, and mucosal blood vessels (at baseline and with nasal complaints)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Consider periodic examinations of urine sediment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21302550\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium (total): Adults: 9.0 to 11.0 mg/dL (2.05 to 2.54 mmol/L), may slightly decrease with aging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM 2011): Sufficient levels in practically all persons: &ge;20 ng/mL (50 nmol/L); concern for risk of toxicity: &gt;50 ng/mL (125 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis patients (NOF [Cosman 2014]): Recommended level to reach and maintain: ~30 ng/mL (75 nmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144087\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Peptide sequence similar to human calcitonin; functionally antagonizes the effects of parathyroid hormone. Directly inhibits osteoclastic bone resorption; promotes the renal excretion of calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption; increases the jejunal secretion of water, sodium, potassium, and chloride</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144105\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypercalcemia: IM, SubQ: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Paget's disease: Within a few months; may take up to 1 year for neurologic symptom improvement</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Hypercalcemia: IM, SubQ: 6 to 8 hours; following multiple doses, hypercalcemic effect diminishes within 24 to 48 hours (Nilsson 1978; Stevenson 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Intranasal: Rapidly but highly variable and lower than IM administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.15 to 0.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized in kidneys, blood and peripheral tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM: 66%; SubQ: 71%; Nasal: ~3% to 5% (relative to IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (terminal): IM 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: SubQ ~23 minutes; Nasal: ~10 to 13 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as inactive metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Salmon calcitonin: 3.1 mL/kg/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144108\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcitonin (Salmon) Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/ACT (3.7 mL): $118.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Miacalcin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/mL (2 mL): $3,243.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144111\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cadens (FR);</li>\n      <li>Calci-10 (TH);</li>\n      <li>Calcinin (TW);</li>\n      <li>Calcitoran (JP);</li>\n      <li>Calco (TH);</li>\n      <li>Calco [salmon] (HU);</li>\n      <li>Calsonin (KR);</li>\n      <li>Calsynar (BR, TW);</li>\n      <li>Calsynar [salmon] (HU, LU);</li>\n      <li>Cibacalcin (AE, BH, CY, EG, GR, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cibacalcine [human] (LU);</li>\n      <li>Citonina (AR);</li>\n      <li>Forcaltonin (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, HU, IE, IL, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Fortical (IL);</li>\n      <li>Karil (LU);</li>\n      <li>Karil [salmon] (LU);</li>\n      <li>Menocal (KR);</li>\n      <li>Miacalcic (AE, AU, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GR, HK, HN, ID, IE, IQ, IR, IS, JO, KR, KW, LB, LK, LY, MT, MX, MY, NO, NZ, OM, PE, PH, PL, PT, QA, RU, SA, SE, SG, SI, SK, SY, TR, TW, VN, YE);</li>\n      <li>Miacalcic [salmon] (HR, HU);</li>\n      <li>Miakaltsyk (UA);</li>\n      <li>Mycalcin (TH);</li>\n      <li>Nozocalcin (BD);</li>\n      <li>Orthonase (TH);</li>\n      <li>Oseum (MX);</li>\n      <li>Osteocal (PH);</li>\n      <li>Salmocalcin (AR);</li>\n      <li>Salmocin (TH);</li>\n      <li>Tendolon (MY);</li>\n      <li>Tonocalcin (MY);</li>\n      <li>Ucecal [salmon] (LU);</li>\n      <li>Zycalcit (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bergqvist E, Sjoberg HE, Hjern B, et al, &ldquo;Calcitonin in the Treatment of Hypercalcaemic Crisis,&rdquo; <i>Acta Med Scand</i>, 1972, 192(5):385-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/5083377/pubmed\" target=\"_blank\" id=\"5083377\">5083377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8263125\"></a>Bilezikian JP. Clinical review 51: Management of hypercalcemia. <i>J Clin Endocrinol Metab</i>. 1993;77(6):1445-1449.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/8263125/pubmed\" target=\"_blank\" id=\"8263125\">8263125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcimar solution (calcitonin-salmon) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/25182228/pubmed\" target=\"_blank\" id=\"25182228\">25182228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeRose J, Singer FR, Avramides A, et al. Response of Paget&rsquo;s disease to porcine and salmon calcitonins. <i>Am J Med</i>. 1974;56(6):858-866.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/4857531/pubmed\" target=\"_blank\" id=\"4857531\">4857531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortical (calcitonin-salmon [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyritis GP, Tsakalakos N, Magiasis B, et al, &ldquo;Analgesic Effect of Salmon Calcitonin in Osteoporotic Vertebral Fractures: A Double-Blind, Placebo-Controlled Clinical Study,&rdquo; <i>Calcif Tissue Int</i>, 1991, 49(6):369-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/1818759/pubmed\" target=\"_blank\" id=\"1818759\">1818759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miacalcin injection (calcitonin-salmon) [prescribing information]. Rockford, IL: Mylan Institutional LLC; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miacalcin nasal spray (calcitonin-salmon) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"358762\"></a>Nilsson O, Almqvist S, Karlberg BE. Salmon calcitonin in the acute treatment of moderate and severe hypercalcemia in man. <i>Acta Med Scand</i>. 1978;204(4):249-252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/358762/pubmed\" target=\"_blank\" id=\"358762\">358762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pontiroli AE, Pajetta E, Scaglia L, et al. Analgesic Effect of Intranasal and Intramuscular Salmon Calcitonin in Postmenopausal Osteoporosis: A Double-Blind, Double-Placebo Study. <i>Aging (Milano).</i> 1994;6(6):459-463.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. <i>Am J Med.</i> 1995;98(5):452-458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/7733123/pubmed\" target=\"_blank\" id=\"7733123\">7733123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reginster JY. Calcitonin for prevention and treatment of osteoporosis. <i>Am J Med.</i> 1993;95(5A):44S-47S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/8256795/pubmed\" target=\"_blank\" id=\"8256795\">8256795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevenson JC. Current management of malignant hypercalcemia. <i>Drugs.</i> 1988;36(2):229-230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-drug-information/abstract-text/3053127/pubmed\" target=\"_blank\" id=\"3053127\">3053127</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9182 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F144121\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F144122\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F144166\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F144125\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F144126\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682377\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682378\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F144099\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F144084\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F24825758\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F144103\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F144102\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F144173\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F144091\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F144106\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F144088\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298928\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218757\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F144095\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1861980\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F144109\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F144110\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F144097\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F21302550\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F144087\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F144105\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F144108\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F144111\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9182|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcitonin-patient-drug-information\" class=\"drug drug_patient\">Calcitonin: Patient drug information</a></li><li><a href=\"topic.htm?path=calcitonin-pediatric-drug-information\" class=\"drug drug_pediatric\">Calcitonin: Pediatric drug information</a></li></ul></div></div>","javascript":null}